A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 45/06 (2006.01) A61K 31/395 (2006.01) A61K 31/41 (2006.01) A61K 31/435 (2006.01) A61K 31/495 (2006.01) A61P 25/00 (2006.01) A61P 37/00 (2006.01) C07D 401/12 (2006.01) C07D 487/04 (2006.01) C07K 5/06 (2006.01) C07K 5/078 (2006.01) A61K 38/00 (2006.01)
Patent
CA 2439691
Co-administration of a melanocortin receptor agonist, particularly an MC-1R or MC-4R agonist, and a cAMP phosphodiesterase inhibitor is described for modulating levels of cyclic adenoise 3',5' monophosphate (cAMP) in a mammal. The inventive co-administration is useful in the treatment of diseases affected by activity of cAMP-PDE, including without limitation, inflammatory bowel disease, irritable bowel syndrome, rheumatoid arthritis, osteoarthritis, pancreatis, psoriasis, migraine, Alzheimer's Disease, Parkinson's disease, transplant rejection, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, stroke, and neurodegeneration of, and consequences of traumatic brain injury.
L'invention concerne la co-administration d'un agoniste du récepteur de la mélanocortine, en particulier un agoniste MC-1R ou MC-4R, ainsi qu'un inhibiteur de phosphodiesterase AMPc destiné à moduler les taux d'adénoise 3',5' monophosphate cyclique (AMPc) chez un mammifère. On utilise cette co-administration dans le traitement de maladies affectées par l'activité de AMPc-PDE, notamment les maladies intestinales inflammatoires, le syndrome de l'intestin irritable, l'arthrite rhumatoïde, l'arthrose, la pancréatite, le psoriasis, les migraines, la maladie d'Alzheimer, la maladie de Parkinson, le rejet de greffe, l'asthme, le syndrome de détresse respiratoire aiguë, la maladie obstructive respiratoire chronique, l'accident vasculaire cérébral, la neurodégénérescence et les conséquences du traumatisme cérébral.
Carlson Kenneth E.
Macor John E.
Bristol-Myers Squibb Company
Gowling Lafleur Henderson Llp
LandOfFree
Co-administration of melanocortin receptor agonist and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Co-administration of melanocortin receptor agonist and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Co-administration of melanocortin receptor agonist and... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1429923